16 (UPI) --The Food and Drug Administration on Friday approved the first over-the ... particularly if they also suffer from kidney disease, a new clinical trial shows. The manufacturer of Ozempic ...

A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval ... them a Novartis drug recently awarded accelerated approval.

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Travere Therapeutics TVTX announced that the FDA ... approval to its oral non-immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.

progressive kidney disease and a leading cause of kidney failure due to glomerular disease. The FDA early last year had granted conditional approval of the drug, subject to confirmatory study results.

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression ...

Novartis’ $3.2 billion deal for Chinook Therapeutics gave the Swiss Big Pharma such a taste for kidney disease ... own iptacopan scored FDA approval in IgAN. That drug, marketed as Fabhalta ...

Novartis has claimed accelerated approval from the FDA for a second ... are at risk of rapid disease progression, making it the first complement inhibitor for the rare kidney disease.

Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in ...

The common, but serious, complication of chronic kidney disease is often seen in patients on hemodialysis. Upacicalcet is already approved for SHPT in Japan, where the drug “performed ...